Unity Health Toronto, Toronto, Ontario, Canada.
Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada.
Pharmacoepidemiol Drug Saf. 2022 Jul;31(7):779-787. doi: 10.1002/pds.5443. Epub 2022 Apr 30.
We sought to compare trends in opioid purchasing between developed and developing economies to understand patterns of opioid consumption, and how they were impacted by the COVID-19 pandemic.
We conducted a retrospective cross-sectional study of retail pharmacy opioid sales from 66 jurisdictions between July 2014 and August 2020. We measured monthly population-adjusted rate of opioid units purchased, stratified by development group and country, and used interventional time series analysis to assess the impact of the COVID-19 pandemic on rates of opioid purchasing among developed and developing economies separately.
Rates of opioid purchasing were generally higher among developed economies, although trends differed considerably by development group. Rates of opioid purchasing declined 23.8% (95% confidence interval [CI] -34.7% to 3.6%) in the 5 years prior to the pandemic in developed economies, but rose 15.2% (95% CI 4.6%-35.6%) among developing economies. In March 2020 there was a short-term increase in the rate of opioid purchases in both developing (10.9 units/1000 population increase; p < 0.0001) and developed (145.5 units/1000 population; p < 0.0001) economies, which was followed immediately by reduced opioid purchasing of a similar scale in April-May 2020 (-14.8 and -171.8 units/1000 population in developing and developed economies, respectively; p < 0.0001).
The COVID-19 pandemic led to disruptions in opioid purchasing around the world; although the specific impacts varied both between and among developed and developing economies. With global variation in opioid use, there is a need to monitor these trajectories to ensure the safety of opioid use, and adequate access to pain management globally.
我们旨在比较发达国家和发展中国家之间的阿片类药物购买趋势,以了解阿片类药物消费模式及其如何受到 COVID-19 大流行的影响。
我们对 2014 年 7 月至 2020 年 8 月期间来自 66 个司法管辖区的零售药店阿片类药物销售情况进行了回顾性横断面研究。我们衡量了按发展集团和国家划分的每月人口调整后阿片类药物购买单位率,并使用干预时间序列分析分别评估 COVID-19 大流行对发达国家和发展中国家阿片类药物购买率的影响。
阿片类药物购买率在发达国家普遍较高,尽管不同发展集团的趋势差异很大。在大流行前的 5 年中,发达国家的阿片类药物购买率下降了 23.8%(95%置信区间 [CI] -34.7%至 3.6%),而发展中国家则上升了 15.2%(95% CI 4.6%-35.6%)。2020 年 3 月,发展中国家和发达国家的阿片类药物购买率都出现了短期增加(分别为 10.9 个单位/每 1000 人增加;p<0.0001)和 145.5 个单位/每 1000 人增加(p<0.0001),随后在 2020 年 4 月至 5 月立即减少了类似规模的阿片类药物购买(发展中国家和发达国家分别减少了 14.8 个单位/每 1000 人和 171.8 个单位/每 1000 人;p<0.0001)。
COVID-19 大流行导致全球范围内的阿片类药物购买出现中断;尽管具体影响在发达国家和发展中国家之间存在差异。由于全球阿片类药物使用情况存在差异,因此需要监测这些趋势,以确保全球范围内阿片类药物使用的安全性和获得足够的疼痛管理。